CURX — Curanex Pharmaceuticals Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2025942 ·
Last close
$4.44
Market Cap
$6.96M
52W High
$13.34
52W Low
$3.58
ADV30
8,586
Next earnings
—
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,325,560 -3,290,970 5,073,932 2,938,463 286,254
Mar 2026 0 — -3,183,359 -3,150,228 8,411,292 4,018,574 332,644
Dec 2025 0 — -3,092,639 -3,073,118 11,580,124 4,973,134 361,040
Sep 2025 0 — -951,327 -954,059 14,478,157 5,830,537 185,955

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,079,094
Investing CF
—
Financing CF
$14,908,695
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.44
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-11,288,753
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-10,464,285
Pretax Income TTM
$-10,468,375
Interest Exp TTM
$4,090
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -4,239,076 -4,225,106 11,580,124 361,040 11,219,084 -10,484,452
Dec 2024 0 -290,386 -361,506 517,935 14,575 503,360 -555,575
Dec 2023 0 -19,298 -19,198 74,366 14,276 60,090 -120
Dec 2022 26,000 -20,233 -20,233 10,232 0 10,232 3,336

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$5,073,932
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
RKTO Rocket One Inc. $6.97M $0.28 —
APRE Aprea Therapeutics, Inc. $7.00M $0.49 —
ENSC Ensysce Biosciences, Inc. $7.02M $0.36 —
MTVA MetaVia Inc. $7.05M $1.07 —
IMRN Immuron Ltd $6.86M $0.85 —

News headlines (Yahoo Finance, 1h cache)

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
2026-05-14 12:53 · Yahoo
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
2026-04-06 13:17 · Yahoo
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeuti
2026-04-02 12:07 · Yahoo
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
2026-04-08 11:47 · Yahoo
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
2026-03-30 21:35 · Yahoo
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
2026-03-18 12:00 · Yahoo
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
2026-03-12 13:30 · Yahoo
Curanex Forms World Class Scientific Advisory Board
2026-03-05 13:00 · Yahoo
Curanex Provides Operational Update on Key Regulatory Milestones
2026-02-25 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.